about
The Causes of HIV-Associated Cardiomyopathy: A Tale of Two WorldsLong-Term Antiretroviral Treatment Adherence in HIV-Infected Adolescents and Adults in Uganda: A Qualitative StudyNovel functions of PXR in cardiometabolic disease.Effects of recent Virginia AIDS Drug Assistance Program policy changes on diabetes and hyperlipidemia control in people living with HIVThe concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk.Differential subcutaneous adipose tissue gene expression patterns in a randomized clinical trial of efavirenz or lopinavir-ritonavir in antiretroviral-naive patients.Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.The lipid profile of HIV-infected patients receiving antiretroviral therapy in a rural Cameroonian population.rs7903146 polymorphism at transcription factor 7 like 2 gene is associated with total cholesterol and lipoprotein profile in HIV/hepatitis C virus-coinfected patients.A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy.Sensory neuropathy and metabolic risk factors in human immune deficiency virus infected South Africans receiving protease inhibitors.Dyslipidaemia in HIV-1-infected patients receiving protease inhibitors after initial treatment with first-line-based non-nucleoside reverse transcriptase inhibitors: a cross-sectional study.Multimorbidity patterns in HIV-infected patients: the role of obesity in chronic disease clustering.Changes in Lipid Profiles of HIV(+) Adults over Nine Months at a Harare HIV Clinic: A Longitudinal Study.Impact of age on markers of HIV-1 diseaseEvaluation of the adverse reactions of antiretroviral drug regimens in a tertiary care hospitalMACH14: a multi-site collaboration on ART adherence among 14 institutionsApolipoprotein B Gene Polymorphisms and Dyslipidemia in HIV Infected Adult Zimbabweans.The Effectiveness of a Bioactive Food Compound in the Lipid Control of Individuals with HIV/AIDS.Changes in coronary heart disease risk profiles of HIV patients in Zimbabwe over 9 months: a follow-up study.Inflammation-modulating cytokine profile and lipid interaction in HIV-related risk factors for cardiovascular diseases.Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy.HAART to heart: highly active antiretroviral therapy and the risk of cardiovascular disease in HIV-infected or exposed children and adults.Alcoholic Extract of Lotus Leaves Improves Lipid Profile in Rats with HIV Protease Inhibitor-induced DyslipidaemiaCardiometabolic risk among HIV-POSITIVE Ugandan adults: prevalence, predictors and effect of long-term antiretroviral therapy.Metabolic Complications among Korean Patients with HIV Infection: The Korea HIV/AIDS Cohort Study.Acute coronary syndromes in patients with HIV.High incidence of hypertriglyceridemia in a Brazilian cohort of people living with HIV/AIDS undergoing antiretroviral treatment in Belo Horizonte, 2001-2010.Metabolic syndrome in patients on first-line antiretroviral therapy containing zidovudine or tenofovir in rural Lesotho, Southern Africa.Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.Changes in elevated cholesterol in the era of tenofovir in South Africa: risk factors, clinical management and outcomes.Dyslipidemia in ART-Naive HIV-Infected Persons in Nigeria--Implications for Care.A comparison of the predicted risk for cardiovascular disease between HIV-infected and uninfected persons in Korea.High rates of hypertension, diabetes, elevated low-density lipoprotein cholesterol, and cardiovascular disease risk factors in HIV-infected patients in Malawi.Progression of coronary artery disease in a HIV-infected patient previously treated for ascending aorta aneurysm.Effectiveness of n-3 fatty acids in the treatment of hypertriglyceridemia in HIV/AIDS patients: a meta-analysis.Genetic markers associated to dyslipidemia in HIV-infected individuals on HAART.Malnutrition and lipid abnormalities in antiretroviral naïve HIV-infected adults in Addis Ababa: A cross-sectional study.Dyslipidemia and its Correlates among HIV Infected Children on HAART Attending Mbarara Regional Referral HospitalThe association between antiretroviral therapy and selected cardiovascular disease risk factors in sub-Saharan Africa: A systematic review and meta-analysis
P2860
Q26765200-A5469DC1-662B-4E1E-BDB0-9B5443B584CCQ28554577-AFD3A7F4-436C-4C2E-BB06-A13D178C3460Q30251861-3A2A0AA8-27CC-4125-ADE9-3378174B4938Q30301053-6975D2A3-8605-4229-B42D-0A526E689B4BQ33849136-6F13CBDD-6B26-47C4-A832-95AAE2A104D1Q34596899-7D79A509-7590-4E29-8583-A513812424B1Q35103606-5D974883-53F0-4DD5-9DA7-329C9E3A97E2Q35114120-BEAD6DA6-2598-4E1B-B549-3E0C5CF1541AQ35142495-524F1383-82E3-4967-A54C-CE23096D966CQ35899038-112164E0-8972-4A8E-B340-E7E3C07F5BBCQ36086086-5F181987-B3F6-4352-8DFC-28D75064AC56Q36184035-09410CB1-464C-4321-8195-0D37C61A9B31Q36429076-7D29C355-528F-4F05-BE22-BFA6DBC5CD14Q36712750-9FF41A1A-35EE-43BD-9AE8-C9D1BCCC608AQ36763762-F6255EEF-1C1D-4E16-AC27-AD06D062EE0DQ36865445-62865E4B-8678-4523-A72F-3A36F0220B18Q37160388-46D936A5-A16E-4E6B-AE09-221BF4B1E0D7Q37350538-37D5434C-B39A-458A-A7F2-58721C3D31B0Q37373805-9FE8A685-77A8-4610-9940-A43049EC9515Q37381433-EF7D34D7-706E-435B-93EF-3B22C7A4BB28Q37420764-AE7AEF74-E7EE-4E69-A7B7-8D7D81DE2720Q37653029-9DD98D55-08BA-4B1F-83DF-0A9B780D374DQ38021848-717E2475-4F72-4625-813E-D5A6D3D693B2Q38598879-4593EE45-38FF-4CCD-B076-8230EA435BF8Q38650436-51EAC06B-384B-4AC4-A9D7-07F9E7C537E1Q38700560-187F05A8-AF9A-40AD-BBEA-9BEDCA288825Q39009201-8DABE6DE-8FC4-40A9-BEBE-EF93D84321AAQ39078112-2D468AC7-1C94-4DEA-833D-9D509098CFC7Q39155380-CAA51ED7-73FA-4813-AAC6-C89E19FAB561Q39515202-A989281D-F188-44FB-A3A8-886BB1466F35Q40278973-CB8E603B-D96C-4295-BE55-C99876548450Q41694521-1020F66C-6058-4861-86BB-B4A0A3E81104Q42275051-3AF9EB98-5851-4B31-BDF3-23ACBF83DB12Q46160196-9FED22ED-370A-4C87-BD43-5C533CDE118DQ47134933-2A704C1B-DBF5-4155-9F62-A08A671D1C6FQ51829297-22E5C7AE-511A-4677-B7CE-8CC300992510Q51860323-2DE7D30A-2551-407B-8F04-7CB4E4AE329CQ53691588-12F71BC4-F718-452D-8641-8CC3F72C7C96Q56913880-5C1AF4A5-E038-4184-AA72-C3EB9F1E1036Q56990144-90ED3BC6-4BB8-4038-89B6-BF33BB5CA0B7
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
HIV and HAART-Associated Dyslipidemia
@ast
HIV and HAART-Associated Dyslipidemia
@en
type
label
HIV and HAART-Associated Dyslipidemia
@ast
HIV and HAART-Associated Dyslipidemia
@en
prefLabel
HIV and HAART-Associated Dyslipidemia
@ast
HIV and HAART-Associated Dyslipidemia
@en
P2860
P1476
HIV and HAART-Associated Dyslipidemia
@en
P2093
Patrick W G Mallon
P2860
P356
10.2174/1874192401105010049
P577
2011-02-24T00:00:00Z